Entrada Therapeutics (TRDA) COO Dowden gave up 2,528 shares at $7.14 to cover taxes or an exercise price
Insider transactions reported
Nathan J Dowden (President & COO at Entrada Therapeutics Inc., TRDA) reported that they gave up 2,528 shares at $7.14 to cover taxes or an exercise price on Sep 2, 2026. After these transactions the filing shows 196,060 shares held directly.
- Reporting person
- Dowden Nathan J
- Role
- President & COO
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Shares withheld for taxes or exercise price (F) | Common Stock1, 2 | -2,528 | $7.14 | $18.1K | 196,060 direct |
Holdings before and after
- Common Stock: 198,588 to 196,060 direct
Footnotes from the filing
- 1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction codes in this filing
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Dowden report in this TRDA Form 4?
Nathan J Dowden (President & COO at Entrada Therapeutics Inc., TRDA) reported that they gave up 2,528 shares at $7.14 to cover taxes or an exercise price on Sep 2, 2026. After these transactions the filing shows 196,060 shares held directly.
How many TRDA shares does Dowden hold after this filing?
The filing shows 196,060 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code F mean on an SEC Form 4?
Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
Historical context for TRDA
Across the 15 sessions after earlier TRDA headlines, the stock closed higher 7 times and lower 8 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TRDA | SPY |
|---|---|---|---|
| Sep 3, 2026 | Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.8% | +1.0% |
| Aug 5, 2026 | Entrada Therapeutics Reports Second Quarter 2026 Financial Results | -2.5% | -0.2% |
| Jun 2, 2026 | Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Studyand 1 other headline that session | -3.9% | +0.1% |
| May 8, 2026 | Entrada Therapeutics downgraded by H.C. Wainwright | -0.1% | +0.8% |
| May 7, 2026 | Entrada Therapeutics Reports First Quarter 2026 Financial Resultsand 2 other headlines that session | -57.3% | -0.3% |
| Apr 1, 2026 | Cantor Fitzgerald initiated coverage on Entrada Therapeutics | +6.8% | +0.8% |
Earlier insider filings at TRDA
- Sep 3, 2026Chief Financial Officer Wentworth Kory James covered exercise/tax liability with 1,733 shares, decreasing direct ownership by 1% to 117,277 units (SEC Form 4) (for tax liability)
- Aug 31, 2026Large owner Mpm Bioventures 2018, L.P. sold $615,777 worth of shares (86,914 units at $7.08) (SEC Form 4)
- Aug 31, 2026Large owner Mpm Bioventures 2014, L.P. sold $615,777 worth of shares (86,914 units at $7.08) (SEC Form 4)
- Aug 27, 2026Large owner Mpm Bioventures 2014, L.P. sold $461,546 worth of shares (62,714 units at $7.36) (SEC Form 4)
- Aug 27, 2026Large owner Mpm Bioventures 2018, L.P. sold $461,546 worth of shares (62,714 units at $7.36) (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow TRDA and get a push notification the moment its next story breaks.